Drug Profile
101 PGC 005
Alternative Names: 101-PGC-005; 101-PGC-005 ('005)Latest Information Update: 08 Mar 2023
Price :
$50
*
At a glance
- Originator 101 Therapeutics
- Class Antiprotozoals; Antiretrovirals; Antivirals
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II/III COVID 2019 infections
- Phase I Leishmaniasis
- Preclinical Dengue; HIV infections; Zika virus infection
Most Recent Events
- 14 Feb 2023 101 Therapeutics terminates a phase II trial in COVID-2019 infections in Israel due to low enrollment (NCT05195749)
- 15 Dec 2022 101 PGC 005 is available for licensing as of 15 Dec 2022. https://www.101therapeutics.com/pipeline
- 15 Dec 2022 Phase-I clinical trials in Leishmaniasis in USA (unspecified route) Before December 2022 (101 Therapeutics pipeline, December 2022)